This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

$5.9 Billion Immuno-Oncology Assays Market Opportunities to 2024: Breakdown by Product, Technology, Indication and Application - ResearchAndMarkets.com

February 20, 2019

DUBLIN--(BUSINESS WIRE)--Feb 20, 2019--The “Immuno-Oncology Assays Market by Product, Technology, Indication, Application - Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.

The immuno-oncology assays market is expected to grow from USD 2.9 billion in 2018 to USD 5.9 billion by 2024, at a CAGR of 12.7% during the forecast period.

The immuno-oncology assays market is driven primarily by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. However, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are the major factors that are expected to restrain the growth of this market during the forecast period.

The lung cancer segment is expected to grow at the highest CAGR during the forecast period

Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer, and other cancers. The lung cancer segment is expected to be the fastest-growing segment during the forecast period, as major players are focusing on immuno-oncology research for lung cancer owing to its increasing incidence.

Asia Pacific projected to grow at the highest CAGR during the forecast period

The Asia Pacific is projected to record the highest growth rate during the forecast period. Factors such as the growing number of CROs in the region, increasing awareness about early detection of cancer, and the shift of manufacturers’ and suppliers’ focus from developed economies to emerging economies, such as India and China are driving the growth of this regional segment.

The immuno-oncology assays market comprises major providers such as Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). The study includes an in-depth competitive analysis of these key players in the immuno-oncology assays market, along with their company profiles, recent developments, and key market strategies.

Topics Covered

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.3.1 Markets Covered

1.3.2 Years Covered for the Study

1.4 Currency

1.5 Limitations

1.6 Stakeholders

2 Research Methodology

2.1 Primary Data

2.1.1 Key Data From Primary Sources

2.1.2 Key Industry Insights

2.2 Secondary Data

2.2.1 Key Data From Secondary Sources

2.3 Market Size Estimation

2.4 Market Breakdown and Data Triangulation

2.4.1 Assumptions for the Study

3 Executive Summary

4 Premium Insights

4.1 Immuno-Oncology Assays: Market Overview

4.2 North America: Immuno-Oncology Assays Market, By Product and Country (2018)

4.3 Immuno-Oncology Assays Market, By Application (2018 vs 2024)

4.4 Immuno-Oncology Assays Market, By Technology (2018 vs 2024)

4.5 Geographical Snapshot of the Immuno-Oncology Assays Market

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers Rising Incidence of Cancer and Increasing Adoption of Targeted Therapy

5.2.2 Restraints Unfavorable Regulatory and Reimbursement Scenario High Amount of Capital Investments and Low Benefit-Cost Ratio

5.2.3 Opportunities Companion Diagnostics

6 Immuno-Oncology Assays Market, By Product

6.1 Introduction

6.2 Consumables

6.2.1 Consumables Segment Will Continue to Dominate the Immuno-Oncology Assays Market During the Forecast Period

6.3 Software

6.3.1 The Need to Deliver Accurate and Timely Analysis of Diagnostic Tests has Resulted in the Increased Adoption of Software

7 Immuno-Oncology Assays Market, By Technology

7.1 Introduction

7.2 PCR

7.2.1 Emergence of Advanced PCR Technologies to Support Market Growth

7.3 Immunoassay

7.3.1 Immunoassays Have the Potential to Reduce Cancer Mortality Rate by Facilitating the Diagnosis of Cancer in the Early Stage

7.4 NGS

7.4.1 NGS Segment to Register the Highest Growth Rate During the Forecast Period

7.5 Flow Cytometry

7.5.1 Flow Cytometry Plays a Critical Role in Clinical Research Studies

7.6 Other Technologies

8 Immuno-Oncology Assays Market, By Indication

8.1 Introduction

8.2 Lung Cancer

8.2.1 Increasing R&D Activities on Lung Immuno-Oncology Assays is a Key Market Driver

8.3 Colorectal Cancer

8.3.1 High Success Rate of Immuno-Oncology Assays in CRC Treatment Decisions to Drive Market Growth

8.4 Melanoma

8.4.1 Growing Cases of Melanoma to Drive Market Growth

8.5 Bladder Cancer

8.5.1 Bladder Cancer Segment to Witness Slower Growth Owing to the Limited Adoption of Immuno-Oncology Assays

8.6 Other Cancers

9 Immuno-Oncology Assays Market, By Application

9.1 Introduction

9.2 Research Applications

9.2.1 Rising Prominence of Biomarker-Based Drug Development and Clinical Trials to Drive the Research Applications Market

9.3 Clinical Diagnostics

9.3.1 Benefits of Immuno-Oncology Assays are Driving Its Adoption in Clinical Diagnostics

10 Immuno-Oncology Assays Market, By Region

10.1 Introduction

10.2 North America

10.2.1 US Increasing Demand for Immunotherapy Medicine forms a Key Driver of Market Growth in the US

10.2.2 Canada High Burden of Cancer to Drive the Demand for Immuno-Oncology Assays

10.3 Europe

10.3.1 Rising Focus on Biomarker Development in Several EU Countries to Support Market Growth

10.4 Asia Pacific

10.4.1 Increasing Demand for Better Healthcare Services in Developing Economies will Contribute to Market Growth

10.5 Rest of the World

11 Competitive Landscape

11.1 Overview

11.2 Vendor Benchmarking

11.3 Competitive Leadership Mapping

11.3.1 Visionary Leaders

11.3.2 Innovators

11.3.3 Dynamic Differentiators

11.3.4 Emerging Companies

11.4 Market Ranking Analysis, 2017

11.5 Competitive Situation and Trends

11.5.1 Collaborations

11.5.2 Product Launches

11.5.3 Acquisitions

11.5.4 Expansions

12 Company Profiles

12.1 Thermo Fisher Scientific Inc.

12.2 Roche Diagnostics

12.3 Agilent Technologies Inc.

12.4 Illumina Inc.

12.5 Nanostring Technologies Inc.

12.6 Sartorius AG

12.7 Foundation Medicine

12.8 HTG Molecular Diagnostics Inc.

12.9 Qiagen

12.10 Merck

12.11 Perkinelmer

For more information about this report visit https://www.researchandmarkets.com/research/ckgqd6/5_9_billion?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190220005567/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs ,Oncology



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/20/2019 08:59 AM/DISC: 02/20/2019 08:59 AM